New article on brilaroxazine negatives in a phase 3. Vocal latency improvement a finding.
https://revivapharma.com/reviva-announces-new-vocal-biomarker-data-from-phase-3-recover-trial-of-brilaroxazine-in-schizophrenia/
4 Likes
Thanks for sharing.
Would brilaroxazine be a partial agonist like abilify? What would be new about this new drug?
1 Like
I think it is a partial agonist like Abilify. Some early reports are it is more potent, with less side effects than Abilify. The company testing it barely has enough money to continue trials.
According to Japanese patient who organizes info:
“First, it should be noted that the “Mean score reduction” in PANSS total score with brilaroxazine administration is -23.9, which is very large.
Brilaroxazine’s effect size of 0.6 is slightly greater than olanzapine’s 0.56 and risperidone’s 0.55.
[The effect size] is much larger than the same dopamine partial agonists, abilify and rexulti. Abilify is 0.41 and rexulti is 0.26.
The only side effects that occurred in more than 5% of patients in the Phase 3 study were somnolence (7.5%) and headache (6%). They were not severe and
appeared to be generally temporary.
In the Phase 3 study, the percentage of patients who gained weight was about half that of abilify and rexulti.
Brilaroxazine also caused fewer extrapyramidal symptoms and akathisia, occurring in only 0.7%. The incidence of akathisia was 5.1% for rexulti and 11.7% for abilify.”
6 Likes